Form 4 for IRON Disc Medicine, Inc.
Accepted 2026-07-14 18:32:13 ET · period of report 2026-07-13 · accession 0001193125-26-303535 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-14 18:32 | 2026-07-13 | IRON | Quisel John D | CEO, Dir | M - OptEx | $10.68 | +33.0K | 259.1K | +15% | +$352.4K |
| DMT | 2026-07-14 18:32 | 2026-07-13 | IRON | Quisel John D | CEO, Dir | S - Sale+OE | $74.96 | -33.0K | 226.1K | -13% | -$2.47M |
| DMT | 2026-07-14 18:32 | 2026-07-13 | IRON | Quisel John D | CEO, Dir | M - OptEx | $0.00 | -33.0K | 124.6K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-13 | M | A | 25,584 | $9.86 | 251,648 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. |
| 2 | Common | Common Stock | 2026-07-13 | M | A | 7,416 | $13.50 | 259,064 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. |
| 3 | Common | Common Stock | 2026-07-13 | S | D | 9,704 | $74.27 | 249,360 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. |
| 4 | Common | Common Stock | 2026-07-13 | S | D | 16,896 | $74.95 | 232,464 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.62 to $75.50, inclusive. |
| 5 | Common | Common Stock | 2026-07-13 | S | D | 6,400 | $76.05 | 226,064 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.83 to $76.29, inclusive. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-07-13 | M | D | 25,584 | $0.00 | 15,791 | D | $9.86 · — to 2031-09-13 | 25,584 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. (F5) The shares underlying this option are fully vested and exercisable as of the date hereof. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-07-13 | M | D | 7,416 | $0.00 | 124,586 | D | $13.50 · — to 2032-12-28 | 7,416 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. (F6) The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date. |